Despite much uncertainty over the specific function of IL-17 in EAE and multiple sclerosis (MS) and the difficulties in extrapolating the results from mouse research to humans, cumulative data have demonstrated persuasive evidence that IL-17 is a vital pathologic cytokine in EAE and a promising therapeutic target in MS. The gene discussed is IL17A; the disease is myeloid sarcoma.